Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pleural Effusion | 2 | 2022 | 38 | 0.690 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2022 | 109 | 0.530 |
Why?
|
| Fibrinolytic Agents | 2 | 2022 | 131 | 0.520 |
Why?
|
| Chest Tubes | 1 | 2016 | 20 | 0.520 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 139 | 0.480 |
Why?
|
| Pneumonia | 1 | 2016 | 125 | 0.470 |
Why?
|
| Cecostomy | 1 | 2024 | 4 | 0.220 |
Why?
|
| Empyema, Pleural | 1 | 2022 | 12 | 0.190 |
Why?
|
| Infant Formula | 2 | 2015 | 147 | 0.170 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 76 | 0.170 |
Why?
|
| Infant | 5 | 2024 | 3720 | 0.140 |
Why?
|
| Postoperative Complications | 1 | 2024 | 1081 | 0.130 |
Why?
|
| Drainage | 1 | 2016 | 87 | 0.120 |
Why?
|
| Sexual Development | 1 | 2015 | 6 | 0.120 |
Why?
|
| Genitalia, Male | 1 | 2015 | 14 | 0.120 |
Why?
|
| Soy Foods | 1 | 2015 | 20 | 0.120 |
Why?
|
| Genitalia, Female | 1 | 2015 | 19 | 0.120 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2015 | 55 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 639 | 0.110 |
Why?
|
| Child, Preschool | 3 | 2024 | 4062 | 0.110 |
Why?
|
| Child | 4 | 2024 | 7229 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2024 | 5486 | 0.100 |
Why?
|
| Child Development | 1 | 2015 | 201 | 0.100 |
Why?
|
| Young Adult | 3 | 2022 | 4337 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2024 | 6671 | 0.100 |
Why?
|
| Breast Feeding | 2 | 2015 | 197 | 0.090 |
Why?
|
| Adolescent | 3 | 2024 | 6737 | 0.090 |
Why?
|
| Sclerotherapy | 1 | 2011 | 46 | 0.090 |
Why?
|
| Face | 1 | 2011 | 56 | 0.090 |
Why?
|
| Genitalia | 1 | 2009 | 10 | 0.080 |
Why?
|
| Soy Milk | 1 | 2009 | 37 | 0.080 |
Why?
|
| Bottle Feeding | 1 | 2009 | 34 | 0.080 |
Why?
|
| Vascular Malformations | 1 | 2011 | 103 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 1 | 2011 | 166 | 0.080 |
Why?
|
| Breast | 1 | 2009 | 85 | 0.080 |
Why?
|
| Male | 6 | 2024 | 26863 | 0.070 |
Why?
|
| Female | 6 | 2024 | 28262 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2022 | 2457 | 0.060 |
Why?
|
| Humans | 8 | 2024 | 52593 | 0.060 |
Why?
|
| Intensive Care, Neonatal | 1 | 2004 | 24 | 0.060 |
Why?
|
| Length of Stay | 2 | 2022 | 674 | 0.050 |
Why?
|
| Morphine | 1 | 2004 | 106 | 0.050 |
Why?
|
| Organ Size | 2 | 2015 | 231 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2004 | 298 | 0.050 |
Why?
|
| Thrombolytic Therapy | 1 | 2022 | 112 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2004 | 327 | 0.040 |
Why?
|
| Ultrasonography | 2 | 2015 | 424 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 279 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2004 | 591 | 0.040 |
Why?
|
| Hospitalization | 1 | 2022 | 749 | 0.030 |
Why?
|
| Milk | 1 | 2015 | 80 | 0.030 |
Why?
|
| Risk Factors | 1 | 2022 | 3952 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2015 | 2891 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 747 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2011 | 69 | 0.020 |
Why?
|
| Veins | 1 | 2011 | 74 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 1553 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2011 | 174 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2009 | 116 | 0.020 |
Why?
|
| Testis | 1 | 2009 | 72 | 0.020 |
Why?
|
| Ovary | 1 | 2009 | 107 | 0.020 |
Why?
|
| Uterus | 1 | 2009 | 88 | 0.020 |
Why?
|
| Prostate | 1 | 2009 | 117 | 0.020 |
Why?
|
| Arkansas | 1 | 2015 | 2029 | 0.020 |
Why?
|
| Isoflavones | 1 | 2009 | 88 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 558 | 0.020 |
Why?
|
| Soybean Proteins | 1 | 2009 | 162 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1202 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 2291 | 0.020 |
Why?
|
| Time Factors | 1 | 2011 | 3000 | 0.010 |
Why?
|
| Leukomalacia, Periventricular | 1 | 2004 | 12 | 0.010 |
Why?
|
| Intracranial Hemorrhages | 1 | 2004 | 41 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 1545 | 0.010 |
Why?
|
| Infant Mortality | 1 | 2004 | 64 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 222 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2004 | 718 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 13507 | 0.010 |
Why?
|
| Middle Aged | 1 | 2011 | 13096 | 0.010 |
Why?
|
| Adult | 1 | 2011 | 14170 | 0.010 |
Why?
|